08/20/2015 - 11:05am

Hallmark has introduced a new greeting card format called Banner Cards.

08/20/2015 - 11:05am

Designer Greetings recently launched Around the Corner, a line of die-cut, accordion, tri-fold cards with such special features as tip-ons, stamps, glitter and embossing treatments that give the cards a 3-D look. 

08/20/2015 - 10:04am

One of the latest innovations from the Korean market has been face-shaped, paper sheet masks that hydrate skin and brighten the complexion. Natural skin and hair care brand Yes To has taken to this innovation and created the Yes To Grapefruit Pore Perfection Paper Mask infused with vitamin C, witch hazel, grapefruit and aloe leaf juice to help reduce hyperpigmentation, correct skin damage and enhance radiance.

08/20/2015 - 10:03am

Cosmederm Bioscience’s Tri-Calm OTC itch relief solution is quickly climbing the anti-itch treatment product chart with growth of 148.2% to a dollar base of $4.9 million for the 52 weeks ended June 14 across total U.S. multi-outlets, according to IRI.

08/20/2015 - 10:03am

When Procter & Gamble line extended its NyQuil brand identity into the sleep care aisle with the launch of ZzzQuil, the company did more than raise a few eyebrows. That launch awoke an entire category.

08/20/2015 - 10:03am

GlaxoSmithKline’s Flonase may not be on today’s top five bestselling cough-cold-allergy-sinus products list, but it won’t be long until the brand breaks through.

08/20/2015 - 10:02am

OTC buyers sniffing out the next big opportunity within VMS may need only go as far as their nose. Piping Rock Health Products, led by NBTY cofounder Scott Rudolph, is bringing aromatherapy to the mass market with its new Nature’s Truth brand.

08/20/2015 - 10:02am

Since the launch of Nexium 24HR in May of 2014, the brand has generated approximately $300 million, “making it one of the largest and most successful Rx-to-OTC switches,” Ian Read, Pfizer chairman and CEO, recently told analysts.

08/20/2015 - 10:01am

Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million.